We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App





Pluristem Reports Preliminary Data from Its COVID-19 Compassionate Use Program

By HospiMedica International staff writers
Posted on 10 Apr 2020
Print article
Illustration
Illustration
Pluristem Therapeutics Inc. (Haifa, Israel), a regenerative medicine company developing a platform of novel biological therapeutic products, has released positive preliminary data from its compassionate use program, treating seven patients suffering from acute respiratory failure and inflammatory complications associated with COVID-19 with Pluristem’s PLX cells, in three medical centers in Israel.

Pluristem develops novel placenta-based cell therapy product candidates. The company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, ischemia, muscle trauma, hematological disorders and radiation damage. The cells are grown using the company's proprietary three-dimensional expansion technology and can be administered to patients off-the-shelf, without tissue matching.

PLX cells are available off-the-shelf and once commercialized, can be manufactured in large scale quantities, offering a key advantage in addressing a global pandemic. PLX cells are allogeneic mesenchymal-like cells that have immunomodulatory properties that induce the immune system’s natural regulatory T cells and M2 macrophages, and thus may prevent or reverse the dangerous over-activation of the immune system. Accordingly, PLX cells may potentially reduce the incidence and/or severity of COVID-19 pneumonia and pneumonitis leading hopefully to a better prognosis for the patients. Previous pre-clinical findings of PLX cells revealed therapeutic benefit in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal injury which are potential complications of the severe COVID-19 infection. Clinical data using PLX cells demonstrated the strong immunomodulatory potency of PLX cells inpatients post major surgery. Taken together, PLX cells’ potential capabilities with the safety profile observed from clinical trials involving hundreds of patients worldwide potentially position them as a therapy for mitigating the tissue-damaging effects of COVID-19.

For Pluristem’s compassionate use program, all the seven patients approved for treatment with PLX cells exhibited, prior to treatment, respiratory failure due to ARDS, which is a major cause of mortality and required mechanical ventilation in an ICU. Four of the patients also demonstrated failure of other organ systems, including cardiovascular and kidney failure, indicating critical disease and poor prognosis. Six patients completed one week follow up, while the seventh patient was treated on April 5 2020. Preliminary data following treatment with PLX cells demonstrated a 100% survival rate. Four out of the six (66%) patients who completed one week follow up demonstrated improvement in respiratory parameters. Three out of the six (50%) patients who completed one week follow up are in advanced stages of weaning from ventilators. Pluristem now plans to apply for initiation of a multinational regulated clinical trial program for the potential use of PLX cells in the treatment of patients suffering from complications associated with COVID-19.

“We are pleased with this initial outcome of the compassionate use program, and committed to harnessing PLX cells for the benefit of patients and healthcare systems. In order to maximize PLX cells’ impact on patient recovery and to work towards making our treatment widely available, we plan to quickly move forward into a clinical development program,” said Pluristem CEO and President, Yaky Yanay. “Pluristem is dedicated to using its competitive advantages in large-scale manufacturing to potentially deliver PLX cells to a large number of patients in significant need. We believe that research and governmental funding may be available to Pluristem to support the use of PLX cells for patients suffering from COVID-19 and are targeting such funding.”

Related Links:
Pluristem Therapeutics Inc.

BMP Whole Blood Analyzer: GEM Premier ChemSTAT
Gold Supplier
Influenza Type A & B Test
Influenza A+B DUO
New
Cancer Biomarker Test
Xpert Bladder Cancer Detection
New
3 & 5-Part All-In-One Auto Hematology Analyzer
SMT-50

Print article
Radcal

Channels

AI

view channel
Image: AI transforms smartwatch ECG signals into a diagnostic tool for heart failure (Photo courtesy of Pexels)

AI-Based Smartwatch Accurately Detects Heart Failure Using ECG Signals

People with a weak heart pump might not have symptoms, but this common form of heart disease affects about 2% of the population and 9% of people over 60. When the heart cannot pump enough oxygen-rich blood,... Read more

Critical Care

view channel
Image: PATHFAST is a compact immunoanalyzer with superior assay performance (Photo courtesy of PHC Europe)

Benchtop Immunoanalyzer Delivers Lab Quality Results for Cardiology, Intensive Care and Emergency Wards at POC

A compact immunoanalyzer with superior assay performance combines the accuracy of a full-scale lab analyzer with the flexibility of a mobile solution, making it an ideal analysis system for laboratories,... Read more

Surgical Techniques

view channel
Image: Bioelectric medicine could stem excessive blood loss (Photo courtesy of Pexels)

Wearable Neurostimulation Solution Could Stem Excessive Blood Loss in the OR

A wearable neurostimulation solution focused on lessening excessive blood loss could save precious time for surgical teams in the operating room. A collaboration between Spark Biomedical, Inc.... Read more

Patient Care

view channel
Image: The digital stretcher scales are designed specifically for emergent situations in hospitals and emergency rooms (Photo courtesy of DETECTO)

Portable High-Capacity Digital Stretcher Scales Provide Precision Weighing for Patients in ER

For emergency arrivals into a hospital, time is of the essence for gathering patient weights. Now, digital stretcher scales specifically designed for emergent situations in hospitals and emergency rooms... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Business

view channel
Image: The global visualization instruments for MIS market is estimated to surpass USD 21 billion by 2031 (Photo courtesy of Pexels)

Global Visualization Instruments for MIS Market Driven by Increasing Demand for Endoscopy Procedures

The last few years have witnessed an increase in patient preference for medical surgeries that involve fewer incisions. As a result, the demand for visualization instruments, which aid in achieving improved... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.